Montag A & Associates Inc. increased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 17.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,984 shares of the medical instruments supplier’s stock after purchasing an additional 1,172 shares during the quarter. Montag A & Associates Inc.’s holdings in Becton Dickinson and were worth $1,709,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently modified their holdings of BDX. Legacy Advisors LLC increased its position in shares of Becton Dickinson and by 7,000.0% during the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares in the last quarter. FTB Advisors Inc. increased its position in shares of Becton Dickinson and by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares in the last quarter. Penserra Capital Management LLC purchased a new stake in shares of Becton Dickinson and during the fourth quarter worth approximately $136,000. Exane Derivatives increased its position in shares of Becton Dickinson and by 848.6% during the fourth quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 628 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Becton Dickinson and during the fourth quarter worth approximately $160,000. Hedge funds and other institutional investors own 77.50% of the company’s stock.
BDX has been the subject of several research reports. Royal Bank of Canada reiterated a “hold” rating and set a $210.00 price target on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Deutsche Bank set a $260.00 target price on Becton Dickinson and and gave the company a “buy” rating in a report on Friday, December 29th. KeyCorp started coverage on Becton Dickinson and in a report on Friday, January 5th. They issued an “overweight” rating and a $260.00 target price for the company. Finally, Stifel Nicolaus restated a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and an average price target of $237.27.
Shares of Becton Dickinson and Co (BDX) opened at $222.87 on Monday. The stock has a market capitalization of $59,337.46, a price-to-earnings ratio of 23.12, a price-to-earnings-growth ratio of 1.59 and a beta of 1.12. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. Becton Dickinson and Co has a twelve month low of $175.66 and a twelve month high of $248.39.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.33 EPS. equities research analysts anticipate that Becton Dickinson and Co will post 10.94 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is presently 229.01%.
In other news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the completion of the transaction, the director now directly owns 295,753 shares in the company, valued at approximately $64,420,918.46. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/19/montag-a-associates-inc-raises-position-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.